Prevalence of Mycobacterium lentiflavum in cystic fibrosis patients, France by Phelippeau, Michael et al.
Prevalence of Mycobacterium lentiflavum in cystic
fibrosis patients, France
Michael Phelippeau, Jean-Christophe Dubus, Martine Reynaud-Gaubert,
Carine Gomez, Nathalie Stremler Le Bel, Marielle Bedotto, Elsa Prudent,
Michel Drancourt
To cite this version:
Michael Phelippeau, Jean-Christophe Dubus, Martine Reynaud-Gaubert, Carine Gomez,
Nathalie Stremler Le Bel, et al.. Prevalence of Mycobacterium lentiflavum in cystic fibrosis pa-
tients, France. BMC Pulmonary Medicine, BioMed Central, 2015, 15 (131), <10.1186/s12890-
015-0123-y>. <hal-01236255>
HAL Id: hal-01236255
https://hal-amu.archives-ouvertes.fr/hal-01236255
Submitted on 1 Dec 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

RESEARCH ARTICLE Open Access
Prevalence of Mycobacterium lentiflavum in
cystic fibrosis patients, France
Michael Phelippeau1, Jean-Christophe Dubus2, Martine Reynaud-Gaubert3, Carine Gomez3,
Nathalie Stremler le Bel2, Marielle Bedotto1, Elsa Prudent1 and Michel Drancourt1,4*
Abstract
Background: Mycobacterium lentiflavum is rarely isolated in respiratory tract samples from cystic fibrosis patients.
We herein describe an unusually high prevalence of M. lentiflavum in such patients.
Methods: M. lentiflavum, isolated from the respiratory tract of cystic fibrosis patients, was identified using both rpoB
partial sequencing and detected directly in the sputum by using real-time PCR targeting the smpB gene.
Results: M. lentiflavum emerged as the third most prevalent nontuberculous mycobacterial species isolated in cystic
fibrosis patients in Marseille, France. Six such patients were all male, and two of them may have fulfilled the American
Thoracic Society clinical and microbiological criteria for M. lentiflavum potential lung infection.
Conclusions: M. lentiflavum was the third most common mycobacteria isolated in cystic fibrosis patients, particularly in
six male patients. M. lentiflavum outbreaks are emerging particularly in cystic fibrosis patients.
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Background
Mycobacterium lentiflavum is a fastidious nontuberculous
mycobacterium (NTM) isolated from the respiratory tract,
urine, lymph nodes and vertebral-bone specimens [1–4].
M. lentiflavum has seldom been reported in cystic fibrosis
patients, at a much lower prevalence than Mycobacterium
abscessus and Mycobacterium avium [5–8]. Moreover, its
clinical significance is debated because M. lentiflavum is
an environmental organism [9].
As we observed an unusual prevalence of M. lentifla-
vum isolates in clinical samples taken from patients
suffering from respiratory diseases, the objective of this
clinical study was to describe the potential opportunistic
role of M. lentiflavum in cystic fibrosis.
Methods
Detection and isolation of M. lentiflavum
Respiratory tract specimens were prospectively collected
and analyzed in the Reference Laboratory for Mycobacteria
of the Institut Hospitalo-Universitaire Méditerranée Infec-
tion in Marseille, France. After decontamination using 4 %
NaOH-N-acetyl-L-cysteine according to the manufac-
turer’s recommendations (MycoPrep, Becton Dickinson,
Le Pont-de-Claix, France), each specimen was centrifuged
and the pellet was microscopically examined after Ziehl-
Neelsen staining. A 500-μL aliquot was simultaneously
inoculated into a mycobacterial growth indicator tube
(MGIT, Becton Dickinson, Le Pont-de-Claix, France)
and onto a Coletsos slant (bioMérieux, La-Balme-les-
Grottes, France) incubated at 37 °C in a 5 % CO2 at-
mosphere. After Ziehl-Neelsen staining confirmation of
positive cultures, the isolates were identified using
partial rpoB sequencing [10].
Direct detection of M. lentiflavum in sputum samples
was conducted using a specific real-time PCR assay. Briefly,
two primers and a probe were designed to specifically
hybridize theM. lentiflavum smpB gene (Table 1). The spe-
cificity of this assay was checked in silico using the Basic
Local Alignment Search Tool (BLAST) [10]. In vitro as-
sessment of a collection of sixteen Mycobacterium species
(including M. lentiflavum) previously identified by partial
rpoB gene sequencing [11], yielded 100 % sensitivity and
100 % specificity for M. lentiflavum (Additional file 1).
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Statistical analysis
Statistical analysis was performed using EpiInfo v3.5.4
software; p < 0.05 was needed for statistical significance.
Ethics
This work was approved by the IFR48 local ethics com-
mittee at the Faculty of Medicine, under reference num-
ber 07–008. No written consent was needed for this
work in accordance with the ‘LOI n° 2004–800 relative à
la bioéthique’ [Law No. 2004–800 concerning bioethics]
published in the Journal Officiel de la République
Française on 6 August 2004 because no additional
samples were obtained for the study.
Results and discussion
Between January 2010 and September 2014, respiratory
tract specimens (sputum, bronchoalveolar lavages and
bronchial aspirates) collected from 354 cystic fibrosis pa-
tients (235 adults ≥18 years and 119 children <18 years)
with a female/male ratio of 199/155 (56.2 %) were ana-
lyzed for mycobacteria (mean of 13.1 collected speci-
men/patient).
In our series, 25/354 (7.1 %) cystic fibrosis patients
(twelve children and thirteen adults) had at least one
respiratory tract specimen that yielded NTM, including
twelve (48 %) patients with M. abscessus complex myco-
bacteria, eight (32 %) patients with M. avium complex
mycobacteria and six (24 %) patients with M. lentiflavum
(Fig. 1); one patient had both M. avium and M. lentifla-
vum successively isolated during the study. A total of
thirteen M. lentiflavum isolates were identified on the
basis of 99.6 % ± 0.003 % similarity with the reference
M. lentiflavum CIP 105465T partial rpoB sequence
[GenBank:EU109300]. The six M. lentiflavum patients
were co-infected by Staphylococcus aureus, Gram-
negative bacilli and fungi and were all under azithromycin
long-term low-dose prophylaxis (250 mg three times a
week). In two patients, M. avium had been previously
isolated in 2004 and 2012 from respiratory tract speci-
mens (Table 2).
The female/male sex ratio of M. lentiflavum patients
(0/6) significantly differed from that of the NTM positive
cohort (199/155; 56.2 %) (p = 0.007, Fisher exact test)
and from that of patients with another NTM (11/9; 55 %)
Table 1 Probe and primer sequences and protocol for real-time
PCR targeting Mycobacterium lentiflavum
Target gene smpB
Primers
MlentismpB MBF CAACTTGCACATTCCCGAGT
MlentismpB MBR CCCGATCAGTGTGTCGATCT
Probe
MlentismpB MBR 6FAM-TCGCACTCGGAAGTTGTTGTTACATAGGC
Dilution 0.1 nmol/μL then 1/40
The extraction of DNA was performed using the EZ1 DNA tissue kit with a
Qiagen EZ1 extractor Advanced XL (Qiagen, Courtaboeuf, France) according to
the manufacturer’s recommendations. Real-time PCR was performed using a
Biorad CFX96 thermocycler with the FAST qPCR MasterMix Plus No ROX kit
(Eurogentec, Angers, France) according to the manufacturer’s recommendations:
five minutes at 95 °C for activation, followed by 40 cycles of 95 °C for 10 s and
60 °C for 35 secons. Amplification products were analyzed using Biorad software
Fig. 1 Nontuberculous mycobacteria (NTM) isolated from 25/354 cystic fibrosis (CF) patients, January 2010 to September 2014, in Marseille, France.
a The number of the patients with at least one respiratory tract specimen that yielded NTM is shown in bars. NTM are color-coded. M. hominissuis,
Mycobacterium avium subsp. hominissuis; M. massiliense, Mycobacterium abscessus subsp. massiliense; M. bolletii: Mycobacterium abscessus subsp. bolletii.
b Proportion of the pediatric (<18 years) and adult (>18 years) CF patients (nCF = 354) including 25 who yielded NTM including M. lentiflavum, M. avium
complex and M. abscessus complex
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(p = 0.02). It further differed from that of M. avium com-
plex patients (5/3; 63 %) (p = 0.03) and that of M. absces-
sus complex patients (6/6; 50 %) (p = 0.054) (Fig. 2a). The
six M. lentiflavum patients were aged 22.2 ± 11.4 y; the
patients with another NTM were aged 22.1 ± 15.1 y; the
M. avium complex patients were aged 26.5 ± 19.9 y; and
the M. abscessus complex patients were aged 19.2 ± 10.9 y
(no statistical significance; p = 0.56; ANOVA) (Fig. 2b).
Two M. lentiflavum patients were clinically stable, had
only one positive specimen and were classified as ‘colo-
nized’ [12]. The four other M. lentiflavum patients had
between two and four positive sputum specimens and in
two of them, M. lentiflavum isolation occurred contem-
poraneously to the decline of their lung function and
thus may fulfill the American Thoracic Society’s (ATS)
criteria for NTM lung infection [12] (Additional file 2:
Figure S1). Thereafter, the forced expiratory volume
improved during antibiotic treatment for M. lentiflavum.
One of these two infected patients, aged 17, underwent a
double lung-transplant because of poor progression of
cystic fibrosis, two years after M. lentiflavum infection had
been treated with combined rifabutin, clarithromycin and
ethambutol for fourteen months and amikacin for one
week. At the four-month follow-up after transplantation,
microbiological surveys did not yield any further M.
lentiflavum from four separate bronchoalveolar lavages.
In this study, we confirmed the identification of M.
lentiflavum, a fastidious organism usually isolated over a
period of three weeks, using rpoB partial sequencing
[10] and a specific real-time PCR assay targeting the M.
lentiflavum smpB gene. Indeed, M. lentiflavum shares
<96 % similarity regarding the rpoB gene sequence with
closely related species, including Mycobacterium stoma-
tepiae DSM 45059, Mycobacterium florentinum DSM
44852, Mycobacterium genavense FI-06288 and Myco-
bacterium triplex ATCC 700071 [GenBank:HM022213,
HM022205, HM022216 and GQ153311]. Moreover, the
routinely used 16S-23S rRNA intergenic spacer sequen-
cing [5], hsp65 restriction fragment length polymorph-
ism and sequencing [13], and commercial probes for M.
avium complex [7, 8, 13] may not be sufficiently dis-
criminative as, for example, M. lentiflavum shares > 99 %
similarity in the 16S rRNA gene sequence with M.
simiae [1].
M. lentiflavum has emerged over a five-year period as
the third most prevalent NTM isolated from the respira-
tory tract in our cystic fibrosis cohort. Furthermore, we
observed an unexpectedly higher prevalence of patients
(6 out of 354; 1.7 %) showing M. lentiflavum isolation
than other reported epidemiological surveys. Indeed,
only one out of 2912 (0.03 %) French patients [5] and
two out of 2970 (0.06 %) American patients [7] were
reported in previous studies. In addition, a recent epi-
demiology survey of NTM isolated in cystic fibrosis
patients in Turkey revealed nine M. lentiflavum isolates
collected from one young male teenager out of 130
(0.8 %) cystic fibrosis patients [8]. The reason why M.
lentiflavum has only been isolated in male cystic fibrosis
patients remains unexplained. As reported by Bryant
et al. [14], patient-to-patient contamination may be sus-
pected although this type of cross-contamination is very
rare and whole genome sequence analyses would prob-
ably be required to satisfactorily conclude a phylogenetic
link and track transmission events. Moreover, the six pa-
tients described here were treated in two distinct centers
(adult and pediatric) for cystic fibrosis. Environmental
transmission is another hypothesis for such prevalence.
An in-lab contamination hypothesis has been pro-
posed, and eleven non-cystic fibrosis patients yielded
M. lentiflavum isolates (out of more than 800 patients
(≈1.3 %) who yielded at least one mycobacterial isolate)
during the same five-year period. This demonstrates
that M. lentiflavum was isolated every two months on aver-
age and that the probability of in-lab cross-contamination
does exist but remains low.
In order to detect M. lentiflavum rapidly in cystic
fibrosis patients, we developed an ‘in-lab’ real-time PCR
targeting the M. lentiflavum smpB gene. This real-time
Table 2 Clinical presentation of the six cystic fibrosis patients
who yielded Mycobacterium lentiflavum isolates
Mean Standard
deviation
Limits
Age, y 22.2 +/−11.4 [14.6 - 44.1]
Pedatric/Adults 3/3
Male, % 100
FEV, % predicted 67 % +/−19 % [46 – 93 %]
BMI, kg/m2 20 +/−1.9 [17.2 – 22.4]
Infected (met ATS criteria)a 2/6
Diabetes 3/6
Exocrine pancreatic disease 6/6
Pseudomonas aeruginosa 5/6
Stenotrophomonas maltophilia 4/6
Previous NTM isolationb 2/6
MS Staphylococcus aureus 6/6
Aspergillus sp. 5/6
Other co-infectionc 4/6
Azithromycin prophylaxisd 6/6
Lung transplanted after
isolation
1/6
FEV forced expiratory volume, ATS American Thoracic Society, BMI body mass
index, NTM nontuberculous mycobacteria, MS methicillin susceptible
aPatients who fulfilled the American Thoracic Society’s microbiological and
clinical criteria for NTM pulmonary disease [12]
bMycobacterium avium complex
cNocardia sp., Penicillium sp., Serratia sp., Achromobacter sp., Scedosporium sp
d250mg per os three times a week
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PCR proved its ability to identify all M. lentiflavum
isolates specifically. Moreover, our preliminary results
indicate that this real-time PCR may be used as a first
screening step directly performed on heat-inactivated
sputum specimens with good sensitivity and 100 % spe-
cificity. These results have to be compared with trad-
itional laboratory tools (culture and AFB smears) to
clarify its relevance for clinical practice [15] and have to
be validated on larger series of prospectively-collected
sputum specimens, including from patients who had
previously yielded M. lentiflavum in sputum cultures.
M. lentiflavum had been considered to be a harmless or-
ganism. However, this interpretation was recently chal-
lenged by the publication of a few cases with disseminated
M. lentiflavum infections [16–18]. In one case, hemo-
phagocytic lymphohistiocytosis and disseminated M.
lentiflavum infection in a heart-transplanted patient led
to the death of this immune-compromised patient
within ten days [18].
In the present study, two out of six patients fulfilled
the ATS clinical and microbiological criteria for NTM
lung disease [12] and had improved respiratory function
while receiving specific antibiotic therapy. However, ATS
criteria, while they continue to be applied to cystic fibro-
sis patients, are far from specific for such patients where
radiographic findings, which are often associated with
NTM, are commonplace irrespective of colonization.
Moreover, clinical decline occurs in cystic fibrosis for a
multitude of reasons. The antibiotic therapy our patient
received is, moreover, active against a wide range of
respiratory tract pathogens.
In our series, all patients were receiving long-term
azithromycin therapy (Table 2). This use of macrolide in
CF patients was shown to be a risk factor for NTM
infection, especially with M. abscessus [19], by inhibiting
intracellular killing of mycobacteria in macrophage by
impairing autophagic and phagosomal degradation [20].
Such mechanisms may have played a role in the
increase of M. lentiflavum isolation. However, as M.
lentiflavum is usually susceptible to clarithromycin [8],
the fact that patients were receiving macrolide and M.
lentiflavum developed further supports the theory that
this is either an environmental contaminant or a transi-
ent colonizer which has not been exposed to macrolide
for prolonged periods.
Conclusion
M. lentiflavum was the third most common NTM isolated
from male cystic fibrosis patients, although few respiratory
cases had been previously reported, particularly in such
patients. We propose monitoring cystic fibrosis patients’
respiratory tract samples for mycobacteria detection, to
achieve this goal, we propose the use and development of
specific molecular tools such as rpoB partial sequencing
(or a specific real-time PCR which needs to be fully vali-
dated against traditional laboratory tools) to monitor the
presence of M. lentiflavum in each cystic fibrosis center
and reference laboratories for mycobacteria.
Fig. 2 Sex-ratio (a) and age distribution (b) of the 354 cystic fibrosis (CF) patients and 25 patients who yielded nontuberculous mycobacteria
(NTM) including Mycobacterium lentiflavum (n = 6), Mycobacterium avium complex (n = 8) and Mycobacterium abscessus complex (n = 12). * p <
0.05; ** p = 0.053; NS, p > 0.1
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Additional files
Additional file 1: Table S1. Mycobacterium species tested for the
specificity/sensitivity assay of real-time PCR for M. lentiflavum species.
(PDF 43 kb)
Additional file 2: Figure S1. Clinical and microbiological data concerning
two cystic fibrosis patients who yielded more than one M. lentiflavum
isolate and who may fulfill the American Thoracic Society’s clinical and
microbiological criteria for NTM lung infection. BMI: Body Mass Index.
(PDF 121 kb)
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AFB: Acid- Fast Bacilli; ANOVA: analysis of variance; ATS: American Thoracic Society;
BLAST: Basic Local Alignment Search Tool; BMI: Body Mass Index (Supplementary
fugure); CF: cystic fibrosis; NTM: nontuberculous mycobacterium; PCR: polymerase
chain reaction.
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